Clinical features and prognosis of 166 cases of MYC/BCL2 double-expression diffuse large B-cell lymphoma

• Published in: Zhōnghuá xuèyèxué zázhì Vol. 43; no. 9; p. 771
• Main Authors: Tang, S H, Tian, L, Zhao, W, Wang, J, Ke, X Y
• Format: Journal Article
• Language: Chinese
• Published: China 14.09.2022
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Female; Humans; Lymphoma, Large B-Cell, Diffuse - diagnosis; Lymphoma, Large B-Cell, Diffuse - drug therapy; Lymphoma, Large B-Cell, Diffuse - genetics; Male; Middle Aged; Prognosis; Proto-Oncogene Proteins c-bcl-2 - genetics; Retrospective Studies; Young Adult; Lymphoma, large B-cell, diffuse; Clinical features; Prognosis; Gene, BCL2; Double expression lymphoma
• ISSN: 0253-2727
• DOI: 10.3760/cma.j.issn.0253-2727.2022.09.010

To investigate the clinical features and prognosis of MYC/BCL2 double-expression diffuse large B-cell lymphoma (DEL) . The clinical data, including clinical characteristics, survival, and prognostic factors, of 166 patients with DEL treated at Peking University Third Hospital from January 2016 to December 2020 were retrospectively analyzed. A total of 410 patients with diffuse large B-cell lymphoma were collected, including 166 cases (40.5%) of DEL. There were 82 males and 84 females with a median age of 63.5 (21-95) years at diagnosis. A total of 110 patients (66.3%) were aged over 60 years at initial diagnosis, 106 patients (106/163, 65.0%) had elevated lactate dehydrogenase (LDH) at diagnosis, 74 patients (74/160, 46.2%) had β(2) microglobulin level over 3 mg/L at diagnosis, and 107 patients (107/163, 65.6%) had≥2 extranodal involvement. Sixty-five patients (65/166, 39.2%) had B symptoms, 131 patients (131/165, 79.4%) had stage Ⅲ and Ⅳ disease at initial diagnosis, 41 patients (41/161, 25.5%) had an Intern